Compare Salesforce Inc (CRM) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Salesforce Inc vs GSK plc — how do they compare? Salesforce Inc trades at $193.2 (market cap $161.73B), while GSK plc trades at $50.37 (market cap $102.60B). The key difference: Salesforce Inc is the larger of the two by market cap, and GSK plc pays the higher dividend (3.57%). Which is the better fit depends on your goals.
| CRM | GSK | |
|---|---|---|
Market Cap | $161.73B | $102.60B |
Sector | Technology | Health |
52-Week High | $266.23 | $61.18 |
52-Week Low | $150.12 | $38.22 |
Enterprise Value | $191.77B | $123.04B |
Dividend Yield | 0.89% | 3.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Salesforce (CRM) trades at $197.47, showing minimal daily movement (-0.02%) amid recent market volatility. The stock maintains strong fundamentals with consistent earnings beats (Q1 2026 EPS of $3.88 vs $3.13 expected) and robust profitability (77.64% gross margin). Technical indicators show bullish momentum with support at $196 and resistance at $199, though RSI levels suggest potential overbought conditions. Recent news highlights AI-driven growth opportunities but also sector-wide software stock pressures.
CRM presents a compelling investment case with analyst consensus pointing to 17% upside to the $230.83 price target. Strong cash flow generation ($13.09B operating cash flow) and AI monetization progress support growth, but risks include competitive AI landscape and macroeconomic sensitivity affecting software demand. Institutional sentiment remains positive with 75.78% buy ratings.
GSK trades at $50.27, down 3.62% today, with a bearish technical signal but strong fundamentals including a P/E of 16.02 and net income margin of 14.52%. Recent quarters show earnings beats, and the company announced a $2.52 billion cost-saving plan to boost its drug pipeline. Cash flow from operations remains robust at $7.74 billion for 2025.
The outlook is mixed: analyst consensus leans hold (55.18%) amid valuation concerns, but revenue growth and pipeline investments support long-term potential. Key risks include competitive pressures and regulatory uncertainty, as highlighted by recent news on vaccine policies. The stock offers a dividend yield with payments scheduled through 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Salesforce Inc
Salesforce Inc provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
Read more on CRM →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
